BioRestorative Therapies, Inc. (BRTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 150K 300K 450K Q2 '21: 15K Q3 '21: 8K Q4 '21: 5K Q1 '22: 16K Q2 '22: 71.1K Q3 '22: 29K Q4 '22: 3.7K Q1 '23: 31.3K Q2 '23: 64.5K Q3 '23: 30.7K Q4 '23: 19.3K Q1 '24: 35K Q2 '24: 89.1K Q3 '24: 233.6K Q4 '24: 43.3K Q1 '25: 25K Q2 '25: 303.3K Q3 '25: 11.8K Q4 '25: 19.6K Q1 '26: 23.2K Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Gross Profit Quarterly

0 150K 300K 450K Q2 '16: 16.1K Q3 '16: 5K Q4 '16: 6.1K Q1 '17: 7K Q2 '17: 20K Q3 '17: 16K Q4 '17: 38K Q1 '23: 31.3K Q2 '23: 64.5K Q3 '23: 30.7K Q4 '23: 19.3K Q1 '24: 35K Q2 '24: 82.6K Q3 '24: 215.4K Q4 '24: 40K Q1 '25: 22.1K Q2 '25: 294.6K Q3 '25: 1.2K Q4 '25: 18K Q1 '26: 15.8K Q3 '16 Q2 '17 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Operating Income Quarterly

-6M -4M -2M 0 2M 4M 6M Q2 '21: -3.6M Q3 '21: -3.7M Q4 '21: -4M Q1 '22: -5.1M Q2 '22: -4.6M Q3 '22: -4.6M Q4 '22: -4.7M Q1 '23: -5.8M Q2 '23: -3.1M Q3 '23: -3.1M Q4 '23: -3.2M Q1 '24: -4.1M Q2 '24: -2.5M Q3 '24: -2.3M Q4 '24: -2.7M Q1 '25: -4.8M Q2 '25: -3.3M Q3 '25: -3.7M Q4 '25: -3.8M Q1 '26: -3.4M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Net Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q2 '21: -4.1M Q3 '21: -4.2M Q4 '21: -20.4M Q1 '22: -4.8M Q2 '22: -4.7M Q3 '22: -4.7M Q4 '22: -2.7M Q1 '23: -7.2M Q2 '23: -5.7M Q3 '23: 4.8M Q4 '23: -2.3M Q1 '24: -2.2M Q2 '24: -4M Q3 '24: -1.1M Q4 '24: -1.6M Q1 '25: -5.3M Q2 '25: -2.7M Q3 '25: -3M Q4 '25: -3.2M Q1 '26: -2.2M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Cost of Revenue Quarterly

0 7K 14K 21K Q2 '24: 6.5K Q3 '24: 18.2K Q4 '24: 3.3K Q1 '25: 2.9K Q2 '25: 8.7K Q3 '25: 10.6K Q4 '25: 1.6K Q1 '26: 7.4K Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26

Operating Cash Flow Quarterly

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q2 '21: -741.8K Q3 '21: -629.4K Q4 '21: -1.1M Q1 '22: -1.6M Q2 '22: -1.3M Q3 '22: -1.5M Q4 '22: -1.6M Q1 '23: -2.4M Q2 '23: -1.1M Q3 '23: -1.2M Q4 '23: -1.8M Q1 '24: -2.3M Q2 '24: -1.9M Q3 '24: -1.7M Q4 '24: -2.3M Q1 '25: -2.8M Q2 '25: -2.7M Q3 '25: -2.9M Q4 '25: -2.4M Q1 '26: -3.8M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Free Cash Flow Quarterly

-3M -2M -1M 0 1M 2M 3M Q3 '16: -1.2M Q4 '16: -1.1M Q3 '18: -1.4M Q4 '18: -1.6M Q3 '19: -1.7M Q4 '19: -1.8M Q1 '22: -1.7M Q2 '22: -1.4M Q3 '22: -1.5M Q4 '22: -1.7M Q1 '23: -2.4M Q2 '23: -1.2M Q3 '23: -1.2M Q4 '23: -1.8M Q3 '24: -1.8M Q4 '24: -2.4M Q1 '25: -2.8M Q2 '25: -2.7M Q3 '25: -2.9M Q4 '25: -2.5M Q4 '16 Q3 '19 Q2 '22 Q1 '23 Q4 '23 Q1 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 600M 1.2B 1.8B Q2 '19: 17.5M Q2 '20: 1.6B Q1 '21: 729.9K Q2 '21: 795.9K Q3 '21: 838.7K Q1 '22: 3.5M Q2 '22: 3.6M Q3 '22: 3.6M Q1 '23: 3.7M Q2 '23: 3.9M Q3 '23: 12.3M Q1 '24: 6.7M Q2 '24: 8.1M Q3 '24: 8.1M Q1 '25: 8.4M Q2 '25: 8.7M Q3 '25: 9.1M Q1 '26: 17.7M Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q1 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q2 '20: -0.15 Q3 '20: -2.02 Q4 '20: -14.74 Q1 '22: -14.31 Q2 '22: -15.59 Q3 '22: -11.88 Q4 '22: -5.61 Q1 '23: -5.21 Q2 '23: -5.40 Q3 '23: -3.73 Q4 '23: -2.47 Q1 '24: -0.87 Q2 '24: 0.10 Q3 '24: -0.42 Q4 '24: -1.16 Q1 '25: -1.47 Q2 '25: -1.27 Q3 '25: -1.47 Q4 '25: -1.59 Q1 '26: -1.07 Q3 '20 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.